Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastrointestinal/Genitourinary Cancers Clear all
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 22, 2026, 2:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 22, 2026, 2:08 AM EDT
Completed Early Phase 1 Interventional Results available

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

NCT01434342
View directory record Official record
Conditions
Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Nicotine Replacement Patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 22, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

NCT02033551
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
Interventions
Veliparib, Carboplatin, Paclitaxel, FOLFIRI
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jul 22, 2026, 2:08 AM EDT
Completed No phase listed Observational

Association Between Hepatitis C Infection and Renal Cell Carcinoma

NCT01405183
View directory record Official record
Conditions
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Interventions
Hepatitis C testing
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Jul 22, 2026, 2:08 AM EDT
Completed Phase 1 Interventional

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

NCT01625351
View directory record Official record
Conditions
Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions
alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 2:08 AM EDT
Recruiting Not applicable Interventional

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

NCT05649072
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Colorectal Cancer
Interventions
Genetic Testing and Counseling, Screening Form
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

NCT05563272
View directory record Official record
Conditions
Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
Interventions
89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Ltd
Industry
Eligibility
18 Years to 95 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jul 22, 2026, 2:08 AM EDT
Completed Not applicable Interventional

A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery

NCT03115398
View directory record Official record
Conditions
Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer, Cervical Cancer
Interventions
Pedometer-based Walking Program
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 2:08 AM EDT
Recruiting No phase listed Observational

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT04981119
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
Other · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Zinc Supplements in Lowering Cadmium Levels in Smokers

NCT00376987
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
zinc oxide
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 120 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
Interventions
Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 2:08 AM EDT
Recruiting Not applicable Interventional

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

NCT05837767
View directory record Official record
Conditions
Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV, Lobular Breast Carcinoma, Lobular Breast Carcinoma Stage IV, Non Small Cell Lung Cancer, NSCLC, Gastrointestinal Cancer, Gastrointestinal Squamous Cell Cancer, Gastrointestinal Adenocarcinoma, Pancreatic Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Metastatic Solid Tumor
Interventions
Palliative radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 22, 2026, 2:08 AM EDT
Recruiting Not applicable Interventional

Building Connections

NCT07091032
View directory record Official record
Conditions
Cancer Colorectal, Cancer Cervix, Depression, Anxiety, Obesity
Interventions
Treatment as Usual, Building Connections Intervention
Other · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jul 22, 2026, 2:08 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Radiation Therapy on Pelvic Floor Disorders in Women

NCT04623515
View directory record Official record
Conditions
Colorectal Cancer
Interventions
REDCap Questionnaires
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 22, 2026, 2:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Faith Moves Mountains: A Community Based Participatory Research (CBPR) Appalachian Wellness & Cancer Prevention Program

NCT01373320
View directory record Official record
Conditions
Lung Cancer, Cervical Cancer, Breast Cancer, Colorectal Cancer
Interventions
Lay health advisor interactions
Behavioral
Lead sponsor
Nancy Schoenberg
Other
Eligibility
18 Years and older
Enrollment
1,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Whitesburg, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Jul 22, 2026, 2:08 AM EDT
Not listed Not applicable Interventional

Insomnia Interventions in Cancer Survivors

NCT02783079
View directory record Official record
Conditions
Insomnia
Interventions
CBT, MBSR
Behavioral
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Camden, New Jersey • Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Jul 22, 2026, 2:08 AM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 22, 2026, 2:08 AM EDT
Not listed Phase 1 Interventional

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

NCT05989724
View directory record Official record
Conditions
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer
Interventions
SON-DP
Drug
Lead sponsor
Qurgen Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Gilbert, Arizona • Detroit, Michigan • Huntersville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 22, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

NCT02082210
View directory record Official record
Conditions
Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
Interventions
Emibetuzumab, Ramucirumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 22, 2026, 2:08 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers

NCT00579163
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Neoplasms, Uterine Cervical Neoplasms, Leukemia, Lymphoma, Non-Hodgkin
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
992 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 2:08 AM EDT
Not listed Not applicable Interventional

Use of Pedometer Following Radical Cystectomy

NCT04305730
View directory record Official record
Conditions
Bladder Cancer, Ileus, Narcotic Use
Interventions
Use of a pedometer following surgery, Standard of care
Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jul 22, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity

NCT01163552
View directory record Official record
Conditions
Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer, Uterine Cancer, Renal Cell Cancer, Thymic Cancer
Interventions
Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jul 22, 2026, 2:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247
View directory record Official record
Conditions
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions
TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 22, 2026, 2:08 AM EDT